retatrutide phase 2 results obesity nejm 2023 Medscape | The investigational triple GLP-1/GIP/glucagon receptor agonist produced significant weight loss and A1c reduction in people Retatrutide Thailand — How to

Given the medications superior metabolic effects, researchers anticipate at least equivalent cardiovascular benefits, but confirmation awaits trial completion

Lastly, for those who are eligible, metabolic/bariatric surgery should remain part of the conversation, as it is one of the most effective and durable obesity treatments we have

Serena lost 31 lbs* Make your health goals happen on Ro: Lose 20% of your weight with GLP-1s, when paired with healthy diet and lifestyle choices

Weight loss data

Retatrutide is still in clinical trials, so while there arent official rules yet, the study criteria can give a general idea of who it may be intended for